Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Restrict the search for suvorexant to a specific field?

Approximate Matches

13
Related Substance Name

9
Standardized Name

9
Any Name

3
Display Name

1
Code Comments

1
Code Literal

1
Code URL

1
Reference Text / Citation

1
Note

1
WIKIPEDIA

Exact Matches

13
Related Substance Name

1
Display Name

1
Standardized Name

1
Code Literal

1
Any Name

1
WIKIPEDIA

There is one exact (name or code) match for suvorexant

SUVOREXANT

081L192FO9

Search for Structure

Status:

US Approved Rx (2014)

Source:

NDA204569

(2014)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204569

First approved in 2014

Source:

NDA204569

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204569

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Orexin receptor type 1

Orexin receptor type 2

Conditions:

Sleep-onset insomnia

Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R. It has been approved for the treatment of insomnia. The mechanism by which suvorexant exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system is a central promoter of wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

Showing 1 - 10 of 14 results

First page disabled
Previous page disabled
1
Next page
Next page

SUVOREXANT

081L192FO9

Search for Structure

Status:

US Approved Rx (2014)

Source:

NDA204569

(2014)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204569

First approved in 2014

Source:

NDA204569

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204569

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Orexin receptor type 1

Orexin receptor type 2

Conditions:

Sleep-onset insomnia

Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R. It has been approved for the treatment of insomnia. The mechanism by which suvorexant exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system is a central promoter of wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

(2S,3S,4S,5R,6R)-6-(((5S)-1-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-4-(5-METHYL-2-(TRIAZOL-2-YL)BENZOYL)-1,4-DIAZEPAN-5-YL)METHOXY)-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID

63UD4J2NG8

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

(3-(((7R)-4-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)CARBONYL)-4-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANOL

V5V4BX93AT

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

((7S)-4-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-7-(HYDROXYMETHYL)-1,4-DIAZEPAN-1-YL)-(5-METHYL-2-(TRIAZOL-2-YL)PHENYL)METHANONE

BQ3ZED7JDX

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

((7R)-4-(6-HYDROXY-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)-(5-(HYDROXYMETHYL)-2-(TRIAZOL-2-YL)PHENYL)METHANONE

7Z8T8DJW5C

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

3-(((7R)-4-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)CARBONYL)-4-(2H-1,2,3-TRIAZOL-2-YL)BENZOIC ACID

G8R68A764K

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

((7R)-4-(6-HYDROXY-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)-(5-METHYL-2-(TRIAZOL-2-YL)PHENYL)METHANONE

85BCK54NR7

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

SUVOREXANT C-14

88D1JK8STQ

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

PLASMA PROTEIN FRACTION (HUMAN)

6D53G0FD0Z

Status:

Possibly Marketed Outside US

Source:

Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]

Source URL:

https://www.drugbank.ca/drugs/DB13968

First approved in 2013

Source:

BLA125416

Source URL:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=998415d8-9bbe-e5b8-c3b0-3ba0344faacb

Class:

MIXTURE

OREXIN RECEPTOR TYPE 2

AD890S9AKZ

Subunit 1 (444) Similarity Search

Sequence Search

Subunit 1 (444) Similarity Search

Status:

Other

Class:

PROTEIN

Structure of SUVOREXANT

ABSOLUTE

Structure of (2S,3S,4S,5R,6R)-6-(((5S)-1-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-4-(5-METHYL-2-(TRIAZOL-2-YL)BENZOYL)-1,4-DIAZEPAN-5-YL)METHOXY)-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID

ABSOLUTE

(2S,3S,4S,5R,6R)-6-(((5S)-1-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-4-(5-METHYL-2-(TRIAZOL-2-YL)BENZOYL)-1,4-DIAZEPAN-5-YL)METHOXY)-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID

Structure of (3-(((7R)-4-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)CARBONYL)-4-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANOL

ABSOLUTE

(3-(((7R)-4-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)CARBONYL)-4-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANOL

Structure of ((7S)-4-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-7-(HYDROXYMETHYL)-1,4-DIAZEPAN-1-YL)-(5-METHYL-2-(TRIAZOL-2-YL)PHENYL)METHANONE

ABSOLUTE

((7S)-4-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-7-(HYDROXYMETHYL)-1,4-DIAZEPAN-1-YL)-(5-METHYL-2-(TRIAZOL-2-YL)PHENYL)METHANONE

Structure of ((7R)-4-(6-HYDROXY-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)-(5-(HYDROXYMETHYL)-2-(TRIAZOL-2-YL)PHENYL)METHANONE

ABSOLUTE

((7R)-4-(6-HYDROXY-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)-(5-(HYDROXYMETHYL)-2-(TRIAZOL-2-YL)PHENYL)METHANONE

Structure of 3-(((7R)-4-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)CARBONYL)-4-(2H-1,2,3-TRIAZOL-2-YL)BENZOIC ACID

ABSOLUTE

3-(((7R)-4-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)CARBONYL)-4-(2H-1,2,3-TRIAZOL-2-YL)BENZOIC ACID

Structure of ((7R)-4-(6-HYDROXY-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)-(5-METHYL-2-(TRIAZOL-2-YL)PHENYL)METHANONE

ABSOLUTE

((7R)-4-(6-HYDROXY-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)-(5-METHYL-2-(TRIAZOL-2-YL)PHENYL)METHANONE

Structure of SUVOREXANT C-14

ABSOLUTE

SUVOREXANT C-14

Mixture

PLASMA PROTEIN FRACTION (HUMAN)

Protein

OREXIN RECEPTOR TYPE 2

Showing 1 - 10 of 14 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1